Abstract. Protease-activated receptor 1 (PAR1) that can be activated by serine proteinases such as thrombin has been demonstrated to contribute to the development of cardiac remodeling and hypertrophy after myocardial injury. Here, we investigated the mechanisms by which PAR1 leads to hypertrophic cardiomyocyte growth using cultured rat neonatal ventricular myocytes. PAR1 stimulation with thrombin (1 U/ml) or a synthetic agonist peptide (TFLLR-NH 2 , 50 μM) for 48 h induced an increase in cell size and myofibril formation associated with BNP (brain natriuretic peptide) production. This actin reorganization assessed by fluorescein isothiocyanate (FITC)-conjugated phalloidin staining appeared at 1 h after PAR1 stimulation, and this response was reduced by a protein kinase C (PKC) inhibitor, chelerythrine, inhibitors of Rho (simvastatin) and Rho-associated kinase (ROCK) (Y-27632), but not by pertussis toxin (PTX). By Western blot analysis, translocation of PKCα or PKCε from the cytosol to membrane fractions was observed in cells stimulated with thrombin or TFLLR-NH 2 for 2 -5 min. In addition, PAR1 stimulation for 3 -5 min increased the level of active RhoA. Furthermore, inhibitors of PKC and ROCK and Rho abrogated PAR1-mediated increase in cell size. Depletion of PKCα or PKCε by specific small interfering RNA also suppressed both actin reorganization and cell growth. These results suggest that PAR1 stimulation of cardiomyocytes induces cell hypertrophy with actin cytoskeletal reorganization through activation of PKCα and PKCε isoforms and RhoA via PTX-insensitive G proteins.
Introduction
Thrombin, a serine protease involved in the blood coagulation process, has been demonstrated to play an active role in the pathogenesis of cardiovascular disorders induced by inflammation or thrombotic occlusion through stimulation of protease-activated receptor 1 (PAR1) (1 -3) . This newly identified receptor belongs to the Gprotein-coupled receptor superfamily activated by proteolytic cleavage of an extracellular amino-terminus domain to unmask a new NH 2 -terminal sequence that acts as a tethered ligand. The activated PAR1 initiates signal transduction via phosphoinositide breakdown (4) .
In the heart, PAR1 is expressed in neonatal and adult ventricular myocytes and cardiac fibroblasts (5) . An increase in the expression of this receptor has been found in the hearts of patients with ischemic and idiopathic dilated cardiomyopathy (6) and in the left ventricle of a mouse model of chronic heart failure (7) . There is now substantial evidence that PAR1 stimulation modulates several cardiac cell functions, for example, an increase in contractility and the occurrence of arrhythmia (8, 9) . Furthermore, hypertrophic cell growth has been observed in rat neonatal cardiac myocytes after long-term treatment with thrombin (5, 10, 11) and in mouse heart overexpressing PAR1 (12) . However, the molecular mechanism by which PAR1 leads to these functional and morphological changes, especially hypertrophic cell growth, has not been identified.
Reorganization of cytoskeletal structure has been suggested as a key event in the development of cardiac hypertrophy and heart failure resulting from ischemia, hypertension, and cardiomyopathies (13, 14) . Cytoskeletal proteins such as actin, vinculin, and tubulin not only contribute to the morphological integrity by anchoring subcellular structures but also participate in transducing mechanical and chemical stimuli from the cell to the matrix and vice versa, thereby regulating various cell functions including growth. Indeed, actin filament reorganization was observed in phenylephrine-, endothelin-, or cyclic stretch-induced hypertrophied cardiomyocytes (15, 16) and in myocardial tissues from patients with dilated cardiomyopathy (17) . Our preliminary study also showed that this cytoskeletal event characteristic of the hypertrophic phenotype occurs in thrombin-stimulated neonatal rat ventricular myocytes. Furthermore, several studies have shown that protein kinase C (PKC) and the small GTP-binding proteins such as RhoA modulate this cytoskeletal reorganization (18 -20) .
In the present study, we investigated the mechanism of PAR1-mediated actin cytoskeleton reorganization in neonatal rat ventricular myocytes, with respect to the contribution of the PKC and/or Rho-ROCK signaling pathway. Next, we pharmacologically tested the involvement of these signaling pathways in hypertrophic cell growth mediated by PAR1 stimulation.
Materials and Methods

Materials
Thrombin, cytochalasin D, simvastatin, pertussis toxin (PTX), phalloidin (from Arnanita phalloides) -fluorescein isothiocyanate (FITC) conjugate, and bovine serum albumin (BSA) were purchased from Sigma Chemicals (St. Louis, MO, USA). Agonist peptide for PAR1 (TFLLR-NH 2 ) was synthesized by Fuso Pharmaceutical Industries, Ltd., Research and Development Center (Osaka). The purity of peptide was >90%. Chelerythrine and Y-27632 were obtained from Calbiochem (La Jolla, CA, USA). Joklik's modified Eagle's medium (JMEM), Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), penicillin-streptomycin and amphotericin B were obtained from Gibco BRL Life Technologies (Grand Island, NY, USA). Perma fluor aqueous mounting medium was purchased from Shadon/Lipsshaw Co. (Pittsburgh, PA, USA). Anti-α and -ε PKC monoclonal antibodies were purchased from BD Biosciences Pharmingen (San Diego, CA, USA). Anti-brain natriuretic peptide (BNP) polyclonal antibody was purchased from Peninsula Laboratories, LLC (San Carlos, CA, USA). Rhodamine red-conjugated goat anti-rabbit IgG was obtained from Jackson Immunoresearch Laboratories (West Grove, PA, USA), and peroxidase-conjugated goat anti-mouse immunoglobulin was obtained from Zymed Laboratories Inc. (South San Francisco, CA, USA). All other chemicals were obtained from Wako Pure Chemicals (Osaka) and were of the highest purity available.
Preparation of ventricular myocytes and cell culture
All animals were handled in accordance with the "Rules of Animal Experimentation Committee, Kansai Medical University". Ventricular myocytes were isolated from the heart of 0 -1-day-old Wistar-Kyoto rats by the collagenase method. Ventricles from 10 to 16 hearts were removed aseptically, rinsed in sterile saline and placed in 2 -3 ml of JMEM containing 0.1% collagenase. The tissues were minced and then subjected to successive collagenase digestion steps. The minced tissues were first exposed to 5 ml of JMEM containing 0.1% collagenase in a culture tube for 10 min at 37°C in an atmosphere of 95% air and 5% CO 2 . Following this incubation, the tissue fragments were mechanically dispersed by passing them several times through a large-pore pipette. The supernatant from the first digestion was discarded. Successive digestion steps were performed 5 times. All subsequent supernatants were removed and placed in 20 ml of ice-cold DMEM containing 10% FCS, penicillin (100 units/ml), streptomycin (100 μg/ml), and amphotericin B (0.75 μg/ ml). This cell suspension was centrifuged at 750 rpm for 5 min and the resulting pellets were dispersed in the same DMEM followed by filtration through a 100-μm nylon mesh. The cell suspensions were then preplated on tissue culture plastic dishes for 1 h during which time the fibroblasts became attached to the dish. The heart cells that remained in the supernatant were collected and diluted with the same medium at 5 × 10 5 cells/ml. Bromodeoxyuridine (100 μM) was included in the culture medium to inhibit proliferation of non-cardiac myocytes (fibroblasts). Cultures were incubated in a humidified 95% air -5% CO 2 atmosphere at 37°C. After 3 -4 days in culture, cardiomyocyte-rich cells (apparently >90%) were washed twice with DMEM without FCS and incubated in this medium for another 24 h before drug administration.
Immunocytochemistry and cell area measurement
Myocytes cultured on 22-mm coverslips were stimulated with PAR1 agonist in the presence or absence of inhibitors for the indicated periods at 37°C, and finally washed three times with phosphate-buffered saline (PBS). For immunostaining, cells were then fixed with 3% paraformaldehyde at room temperature for 10 min and washed twice with PBS. The fixed cells were permeabilized with 0.4% Triton X for 3 min and were washed twice with PBS. The cells were then incubated with polyclonal antibody against BNP in PBS containing 2% BSA for 3 h at room temperature. The cells were incubated with FITC-labeled phalloidin (0.25 μg/ml) and rhodamine red-conjugated goat anti-rabbit IgG in the dark for 1 h at room temperature. After washing with PBS, coverslips with cells were mounted on a slide and visualized using confocal microscopy (LSM510 Meta; Carl Zeiss, Jena, Germany) using an oil immersion objective lens for high resolution: 4 -6 frames per dish were captured. Aperture, gain, and black level for image acquisition were maintained at a constant level. The area of the fluorescently labeled cells was then determined by image analysis using LSM510 Meta software.
Western blot analysis of PKC translocation
Myocytes were stimulated with PAR1 agonists for the indicated durations followed by harvesting. Preparation of membrane and cytosol was performed at 4°C. The cells were homogenized in a buffer (pH 7.4) containing 20 mM Tris, 1 mM EDTA, 10 mM EGTA, 20 μg/ml leupeptin, 200 U/ml aprotinin, and 0.4 mM phenylmethylsulfonyl fluoride and then centrifuged at 100 × g for 5 min to remove cell debris. The upper fractions were centrifuged again at 100,000 × g for 30 min. The resulting pellet was resuspended in the homogenization buffer, the supernatant being concentrated using centrifugal filtration (Ultrafree MC; Millipore, Bedford, MA, USA); these two components were then saved as membrane and cytosol fractions, respectively. Protein concentrations of samples were measured by the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). The membrane and cytosol fractions were mixed with a sodium dodecyl sulfate (SDS)-Laemmli sample buffer and heated at 100°C for 2 min. Proteins (25 μg) were separated by 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to an immobilon P membrane (Millipore) using an electroblotting apparatus. The membrane was blocked with 5% nonfat milk in Tris-buffered saline (TBS; 50 mM Tris and 150 mM NaCl, pH 7.5) overnight at 4°C. After washing with TBS containing 0.1% Tween 20, the membrane was incubated with specific antibodies for PKCα and PKCε isoforms for 2 h at room temperature. The membrane was then washed and incubated for 1 h with peroxidase-conjugated goat antimouse immunoglobulin. Reactive bands were visualized using an enhanced chemiluminescence method. The signal intensities were determined with Image-J software.
Rho activation assay
Rho activation was determined using the GSTrhotekin-Rho-binding domain (GST-RBD) that specifically binds activated Rho [Rho activation assay Biochem kit (BK036); Cytoskeleton, Inc., Denver, CO, USA]. In brief, myocytes (2 × 10 7 cells/10-cm-diameter culture dish) stimulated with agonists or GTPγS for the indicated durations were washed twice with PBS and lysed with 500 μl cell lysis buffer (pH 7.5) containing 50 mM Tris, 10 mM MgCl 2 , 0.5 M NaCl, 1% Triton X, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 500 μg/ml tosyl arginine methyl ester and then centrifuged at 8,000 rpm for 5 min. For active (GTP-bound state) Rho, the resulting supernatants were transferred to tubes containing GST-RBD beads. After incubation at 4°C for 1 h, the mixture was washed and centrifuged again. The pelleted beads were washed with wash buffer (25 mM Tris, pH 7.5, 30 mM MgCl 2 , 40 mM NaCl) and resuspended in Laemmli buffer. Active Rho samples were resolved by 12% SDS-PAGE and analyzed by Western blotting using polyclonal anti-RhoA antibody. Protein concentrations of the samples were measured by using the Bio-Rad protein assay.
Small interfering RNA (siRNA) synthesis and transfection
siRNAs specific for PKCα and PKCε isoforms were designed using BLOCK-iT RNAi Designer and synthesized by Invitrogen (Carlsbad, CA, USA) (PKCα: 5′-UGAAGAAGCGGGCGAUGAAUUUGUG-3′, PKCε: 5′-UUAAGAAGGCCAUUGAACACUACCA-3′). The duplex siRNAs or control unrelated siRNA (at final concentration of 10 nM) were reverse-transfected into cardiomyocytes using Lipofectamine RNAi/MAX (Invitrogen) according to the protocols recommended by the manufacturer. After 24 h of transfection, complete DMEM (with FCS and antibiotics) was added to the cells followed by an additional incubation for 2 days before experiments.
Statistical analyses
Statistical analyses were performed by ANOVA and post hoc Fisher's test. When only two groups were compared, Student's t-test was used for statistical analysis. The differences between mean values with P-values less than 0.05 were considered significant.
Results
Thrombin or a PAR1-agonist peptide induces morphological changes in rat neonatal cardiac myocyte
Reorganization of the actin cytoskeleton and BNP/ ANP expression are the characteristic features of the hypertrophic phenotype. In the previous report, Glembotski et al. (11) demonstrated that chronic treatment with thrombin promotes myocardial ANF (ANP) expression and cell growth. In the present study, we confirmed similar phenomena. Figure 1 shows FITC-conjugated phalloidin staining of actin filaments and BNP immunoreactivity in neonatal cardiac myocytes in the presence or absence of thrombin (1 U/ml) or a PAR1-agonist peptide (TFLLR-NH 2 , 50 μM). PAR1 stimulation for 48 h induced an increase in myocyte cell size and BNP expression associated with actin cytoskeleton reorganization as assessed by polymerized actin (F-actin) (Fig. 1A) . To further gain insight into the signaling mechanism for this PAR1-mediated change in cytoskeletal structure, we firstly studied the time course of the cytoskeletal response. There was a slight basal actin organization under the serum-free condition. PAR1 stimulation with thrombin or TFLLR increased actin organization at 1 h, and these responses persisted thereafter (Fig. 1B) . In the subsequent experiments, therefore, the analysis of this cytoskeletal response was performed at 1 h after receptor stimulation.
PKC and Rho/ROCK inhibitors reduced PAR1 stimulation-induced actin cytoskeleton reorganization
PKC and/or small G-protein Rho have been shown to induce actin reorganization (19, 20) . To elucidate whether these signaling molecules play a role in the PAR1-mediated changes in cardiac cell structure, the myocytes were pretreated with the PKC inhibitor chelerythrine (1 μM (21) . As shown in Fig. 2 , these inhibitors reduced thrombin-or TFLLR-NH 2 -induced reorganization of Factin. However, this reorganization of F-actin was not inhibited by PTX (100 ng/ml) (22) treatment. These findings suggest that PAR1 stimulation induces these morphological responses probably through PKC and Rho/ ROCK activation via PTX-insensitive G proteins. Each inhibitor alone did not affect the cell morphology.
PAR1 stimulation activates PKCα and PKCε
Cardiac myocytes express several PKC isoforms, two of which, PKCα and PKCε, are reportedly activated by hypertrophic stimulators such as phenylephrine and endothelin (19, 23) . Furthermore, when activated by extracellular stimuli, these PKCs are translocated from the cytosol to the plasma membrane to exert kinase activities. To explore the possibility that PKC activation is responsible for actin reorganization in response to PAR1 stimulation, we performed Western blot analyses using two PKC isoform-specific antibodies. Exposure of cardiac myocytes to thrombin (1 U/ml) for 2 -5 min induced an increase in the amounts of immunoreactive PKCα (molecular mass, 78 kDa) and PKCε (97 kDa) isoforms in the membrane fractions associated with a concomitant decrease in the cytosol fractions, compared with each control (no treatment) (Fig. 3A) . Similar effects on the subcellular localization of PKCα and PKCε were obtained with the cells stimulated with the PAR1 agonist peptide (TFLLR-NH 2 , 50 μM) for 2 -5 min (Fig. 3B) . The bar graphs show the pooled data obtained from four to five cultures derived from four separate experiments. As shown by densitometric analyses, redistribution of these isoforms occurred within 2 min and persisted thereafter in the presence of each PAR1 agonist. These findings suggest that PAR1 stimulation results in immediate activations of PKCα and PKCε.
PAR1 stimulation enhances the level of active RhoA
Since RhoA cycles between an active, GTP-bound state, and an inactive, GDP-bound state, we examined whether PAR1 stimulation can induce RhoA activation using the affinity-binding assay for active RhoA, as described in the Materials and Methods section. Western blot analyses using an active-RhoA-specific antibody revealed that stimulation of cardiac myocytes with thrombin (1 U/ml) for 5 min increased the level of GTPbound RhoA (21 kDa) in the cell lysate (Fig. 4) . As a positive control, stimulation with GTPγS (200 μM), a non-hydrolysable GTP analog, for 15 min also induced marked activation of RhoA, which confirmed the reliability of our detection system. Treatment with TFLLR-NH 2 (50 μM) for 3 or 5 min also induced a clear increase in the level of active RhoA. This response was partially reduced in the presence of chelerythrine (1 μM).
Inhibitors of PKC, Rho/ROCK, and actin polymerization attenuate the PAR1-mediated increase in cell size
Next, we examined whether the PAR1-mediated increase in cell size depends on the actin cytoskeleton reorganization regulated by PKC and/or ROCK. Cardiomyocytes were pretreated with chelerythrine, Y-27632, or simvastatin for 20 min or 2 h (in case of simvastatin) and then stimulated with thrombin (1 U/ml) or TFLLR-NH 2 (50 μM) for 48 h. As shown in Fig. 5 , these inhibitors attenuated the thrombin-or TFLLR-NH 2 -induced increase in cell size. Furthermore, simultaneous application of chelerythrine and Y-27632 resulted in a significant reduction of TFLLR-induced cell growth (813.9 ± 74.0, **1373.3 ± 124.4, or 843.4 ± 44.1 μm 2 in the control, TFLLR-treated, or TFLLR plus two inhibitors-treated group, respectively, n = 5, **P < 0.01 vs. control), compared to that by each inhibitor alone. In addition, the actin polymerization inhibitor cytochalasin D (0.1 μM) markedly reduced TFLLR-NH 2 (50 μM)-induced cell growth (cell area: 1404.8 ± 114.3 vs. **916.2 ± 45.5 μm 2 with or without cytochalasin D, respectively, n = 5; **P < 0.01, compared with TFLLR-NH 2 alone). These results suggest that PKC-and ROCK-regulated F-actin reorganization is an important factor for PAR1-mediated cell growth. 
Inhibition of the PAR1-mediated F-actin reorganization and cell growth by PKCs gene knockdown
Since chelerythrine has broad specificity against PKC isoforms, final experiments were performed to confirm the involvement of PKCα and PKCε isoforms in PAR1-mediated cellular responses using siRNAs specific for PKCα and PKCε isoforms. Unrelated siRNA was used as a negative control. Western blot analysis of PKCα or PKCε siRNA transfection showed a significant decrease in PKCα or PKCε protein expression in cardiac myocytes as compared to unrelated siRNA or the control, although β-actin expression was unchanged (Fig. 6A) . As shown 
Discussion
Our results demonstrate that PAR1 stimulation of cardiomyocytes with thrombin or TFLLR-NH 2 for 48 h induced cell hypertrophic responses characterized by increases in cell size and actin reorganization. These findings are consistent with the previous report (11) demonstrating that thrombin regulates myocardial cell gene (atrial natriuretic factor) expression and growth through a chelerythrine-inhibitable pathway. In the present study, these cellular responses were reduced in the presence of inhibitors of PKC or ROCK. Therefore, the PKC and/or Rho/ROCK-regulated mechanism is thought to underlie PAR1-mediated hypertrophic growth. This hypothesis is supported by the fact that PKCα and PKCε isoforms and RhoA were activated in cardiac cells under PAR1 stimulation (Figs. 3 and 4) . As for the thrombin action, this protease reportedly activates not only PAR1 but also PAR4 (2). So it is possible that PAR4 also participates in the thrombin-induced effects in the present study.
In general, the PAR family is known to contribute to cell proliferation and growth in several types of cells including cardiac cells (4, 5) . To clarify the process of PAR1-mediated cell growth, we focused on the signaling mechanism of myofibril formation and reorganization (F-actin polymerization), which was generally found in hypertrophied myocytes in response to phenylephrine or endothelin (15, 16) . In our experimental system, a slight actin organization was observed in the basal state. PKCor RhoA-independent regulatory mechanisms [for example, focal adhesion kinase (FAK) or Src etc.] (14) may be involved in this phenomenon because either chelerythrine or Y-27632 did not have any effect. In the present study, we found that PAR1 causes F-actin organization at 1 h after PAR1 stimulation. Such an early induction of cytoskeletal response was also demonstrated in rat neonatal cardiomyocytes subjected to various hypertrophic stimuli (24 -26) . Although a correlation between myofibril formation and myocyte growth is currently unknown, this cytoskeleton reorganization may contribute to the development of cell hypertrophy through the promotion of nuclear transport of active extracellular signal-regulated kinase (ERK), an important transcriptional factor for cell growth, as has been proposed in stretched (25) or leptin-stimulated cells (26) . Although the inhibitory effect of cytochalasin D on cell growth is consistent with this hypothesis, interpretation of this event needs caution. It is possible that cytochalasin D inhibited hypertrophic cell growth through another mechanism such as reduction of glucose uptake resulting from inhibition of actin polymerization because actin organization has been demonstrated to regulate glucose uptake by modulating glucose transporter trafficking (27) . In previous reports using airway epithelial cells, we showed that PAR regulates cytoskeletal structure as well as cell function such as neutrophil adhesion through PKC-and/or Rho-dependent signaling (28, 29) . Furthermore, it was demonstrated that PKC and RhoA act in concert as mediators of actin cytoskeleton organization (18, 30) . Although the functional role of these signaling molecules remains unclear, tyrosine phosphorylation of actin-associated proteins, namely, FAK and paxillin, is shown to be a key event for myofibril formation (19, 24) . In line with these notions, pharmacological inhibition of PKC, Rho, or Rho kinase using chelerythrine, simvastatin, or Y-27632 and gene knockdown using PKCs siRNA reduced PAR1-mediated myofibril formation and reorganization (Figs. 2 and 6 ). Furthermore, these pharmacological and gene strategies also inhibited enhancement of cell size, confirming that PKC and Rho act as early mediators of PAR1 responses. Some reports have described that PKC resulting from Gq-coupled phosphoinositide breakdown leads to RhoA activation (31, 32) . This signaling cascade may at least in part be involved in the present case since TFLLR-NH 2 -induced RhoA activation was partially inhibited by the PKC inhibitor (Fig. 4) . However, the possibility that another PKC-independent mechanism, such as direct stimulation via G 12/13 protein (22, 33) , participates in the RhoA activation process cannot be ruled out. Taking these observations and little effect of PTX against F-actin reorganization (Fig. 2) into consideration, PAR1 stimulation could trigger both PKC-and RhoA/ROCK-dependent signaling pathways presumably via Gq and G 12/13 proteins. The exact relationship between PKC and RhoA is not fully clarified in the present study. However, since simultaneous application of both chelerythrine and Y-27632 resulted in a significant reduction of TFLLR-induced cell growth compared to each inhibitor alone, coordinated interaction between these pathways may be necessary for actin cytoskeletal reorganization in cardiomyocytes. This issue is a subject for future study.
In conclusion, in cardiac ventricular myocytes, PAR1 stimulation induces cell hypertrophic growth presumably through the actin cytoskeleton reorganization via activation of PKCα and PKCε isoforms and RhoA. Inhibition of these signaling pathways may be a new strategy to protect against the hypertrophy induced by inflammationrelated heart diseases such as myocardial infarction.
